Aiding and informing the diagnosis of many diseases requires accurate diagnostic tools, many of which require protein (e.g. monoclonal antibody) components for their readouts, and biological manufacturing systems for reagents. Understanding that diagnostic products have a significantly lower demand in terms of scalability and absolute amounts of protein, Aragen routinely scales down the therapeutic CHO-DG44 cell line development process, to enable those requirements in a robust, reproducible and cost-effective manner.
20+ years experience in executing parallel processing and focused analytics to mitigate risks to client programs and shorten the timeline to IND, with scalable and reproducible processes.
FAQ
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit
